Category Archives: Psoriasis

As the United States looks to combat vaccine hesitancy, at least one group is feeling even more confident in a vaccinebut not the COVID-19 shot: Patients with autoimmune rheumatic diseases (ARDs) had a higher rate of flu vaccinations during the pandemic, researchers discovered.

A total of 1,015 patients were interviewed. A greater proportion of patients received the flu shot during the pandemic (2020-21 season) than before (2019-20 season). Fewer than 1% of patients who got the shot reported disease flares.

In the pre-pandemic period, patients were more likely to say their rheumatologist did not recommend the shot compared to during the pandemic. During both flu seasons, other reasons patients skipped out on the shot included they didnt think it would have any benefit, they didnt feel it was safe, and other.

Another study analyzed the prevalence of and risk factors for venous thromboembolism (VTE) in patients with psoriasis and psoriatic arthritis (PsA). Final analysis included 2,433 patients, and there were 26 incident VTEs. The incident rate of the first VTE was 12 events per 10,000 patient-years. By age 80, 4.6% of patients had developed their first VTE. Factors independently correlated with VTE were older age, diabetes mellitus, and corticosteroid usage.

Finally, a study compared golimumab treatment retention among patients with rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA), and PsA. Compared to patients with RA, those with AxSpA or PsA had higher rates of retention. Further, retention rates were higher when golimumab was a first-line treatment instead of third or later. Use as first-line biological therapy, having AxSpA or PsA (instead of RA), and concomitant methotrexate therapy were all correlated with increased golimumab retention, while steroid use reduced retention.

In Case You Missed It

Flu Shot Rates Increased During COVID-19 Pandemic among Patients with Autoimmune Rheumatic Diseases

Risk Factors for VTE in Patients with Psoriasis, Psoriatic Arthritis

Golimumab Treatment Retention Comparison: RA, AxSpA, and PsA

The rest is here:
Rheum Round-up: More Rheumatic Pts Got Flu Shot, VTE in PsA, and more - DocWire News

The Global Psoriasis Therapeutics Market Research Report 2021-2027 is a significant source of keen information for business specialists. A report published by Market Insights Reports is an overall investigation and thorough information in regards to the market size and market elements of the Psoriasis Therapeutics. It furnishes the business outline with development, historical and futuristic cost analysis, income, demand, and supply information (upcoming identifiers). The research analysts give a detailed depiction of the worth chain and its wholesaler examination. The Psoriasis Therapeutics market study gives extensive information which upgrades the agreement, degree, and use of this report. This is a latest report, covering the COVID-19impact on the market.

Click the link to get a Free Sample Copy of the Report-

https://www.marketinsightsreports.com/reports/04012768936/global-psoriasis-therapeutics-market-size-status-and-forecast-2021-2027/inquiry?Mode=Akkshata

Top Companies in the Global Psoriasis Therapeutics Market are Astellas Pharma Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, F. Hofffmann-La Roche, GlaxoSmithKline plc, Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., Biocon Limited, Eli Lilly and Company, G & W Laboratories Inc.

This report fragments the Global Psoriasis Therapeutics Market based on Types are-

TNF Inhibitors

PDE4 Inhibitors

Interleukin Blockers

Others

Based on Application, the Global Psoriasis Therapeutics Market are divided into-

Oral

Parenteral

Topical

The current Psoriasis Therapeutics market possibilities of the sector additionally have been analyzed. Furthermore, prime strategical activities in the market, which incorporate product advancements, and acquisitions, partnerships are discussed. Psoriasis Therapeutics Organization Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products, and so on)

Get exclusive discount on this report

https://www.marketinsightsreports.com/reports/04012768936/global-psoriasis-therapeutics-market-size-status-and-forecast-2021-2027/discount?Mode=Akkshata

Geographic Coverage-

The report contains detailed country-level analysis, market revenue, market value and forecast analysis of ingestion, revenue and Psoriasis Therapeutics market share,growth speed, historical and forecast (2016-2027) of these regions are covered:

Explore Full Report With Detailed TOC Here:

https://www.marketinsightsreports.com/reports/04012768936/global-psoriasis-therapeutics-market-size-status-and-forecast-2021-2027?Mode=Akkshata

Reasons for purchasing this Report-

Finally, Psoriasis Therapeutics Market report is the credible hotspot for acquiring statistical market that will exponentially grow your business. The report gives the guideline area, monetary circumstances with the product value, advantage, limit, generation, supply, solicitation, and market improvement rate and figure, etc. Psoriasis Therapeutics Market report furthermore Presents another SWOT assessment, theory feasibility examination, and venture return investigation.

We additionally offer customization on reports based on customer necessity:

1- Country-level analysis for any 5 countries of your choice.

2- Competitive analysis of any 5 key market players.

3- 40 analyst hours to cover any other data points.

All the reports that we list have been tracking the impact of COVID-19 on the market. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check with the sales team.

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information, and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

sales@marketinsightsreports.com | irfan@marketinsightsreports.com

Continue reading here:
Psoriasis Therapeutics Market 2021 Size, Status and Business Outlook Astellas Pharma Inc., AstraZeneca plc, Boehringer Ingelheim GmbH The Courier -...

Last November and then again in February, Bristol Myers Squibb said its oral drug designed to treat psoriasis differently from currently approved medicines had achieved the goals of large Phase 3 clinical trials.

On Friday, the actual data from those two studies were presented publicly for the first time at the annual meeting of the American Academy of Dermatology. The Bristol drug, called deucravacitinib, proved more effective at clearing the chronic skin disease numerically and statistically compared to a placebo and a competing drug from Amgen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

Read the original:
New data point to benefits of Bristol's novel psoriasis pill, but safety issues will be scrutinized - STAT

Psoriasis is an autoimmune condition that causes skin cells to build up and form lesions on the skin. Food is one of many potential triggers that may make a persons psoriasis symptoms worsen or flare.

People with psoriasis are at a greater risk of developing other conditions, including obesity, type 2 diabetes, and cardiovascular disease.

Making dietary adjustments may help prevent these secondary conditions and reduce symptoms.

Certain foods may act as triggers for some people.

This article explores what foods may trigger psoriasis flares and how a person can identify them.

Gluten is a protein in certain grains, including wheat. For example, bread, pasta, and baked goods contain gluten in varying amounts.

Celiac disease is an autoimmune disease that causes a reaction to gluten when a person consumes products that contain wheat.

A 2018 study found that people with psoriasis had the same prevalence of an antibody that people with celiac and gluten sensitivities have.

Researchers also found that when people who tested positive for the antibody ate a gluten-free diet, they saw a reduction in their psoriasis symptoms.

Learn more about how a gluten-free diet might help with psoriasis here.

Red meat contains a polyunsaturated fatty acid called arachidonic acid. These fats create byproducts that contribute to psoriasis lesions.

As a result, avoiding red meat, such as hamburgers or steak, may help reduce the severity of psoriasis lesions.

Avoiding red meats has the added benefit of helping to prevent heart disease.

According to some research, red meats create byproducts that increase a persons likelihood of developing heart disease.

For a person living with psoriasis, avoiding red meat may help prevent heart disease even if it does not affect their psoriasis symptoms.

Learn more about red meat and health here.

Like red meat, dairy also contains arachidonic acid.

A 2017 review suggested that the arachidonic acid in dairy products may irritate the intestinal tracts inner lining and worsen psoriasis symptoms.

However, researchers called for more studies to confirm this link.

Anecdotal evidence suggests that some people have experienced fewer psoriasis symptoms after eliminating dairy from their diets.

Another 2017 study investigating the effects of diet on psoriasis, reported that one of the most common food triggers participants chose to remove from their diets was dairy.

Learn about how to replace dairy in the diet.

Processed foods can contribute to various health conditions, including type 2 diabetes, obesity, and heart disease.

Obesity has associations with inflammation and an increase in the severity of psoriasis symptoms.

A person with psoriasis who also has obesity may find that cutting out or reducing processed foods may also help them manage their weight. This could improve their psoriasis symptoms.

The term processed food means any food that manufacturers change during production.

Learn more about processed foods here.

Caffeine may trigger psoriasis flares in some people.

Some research indicates that people with psoriasis could consider avoiding caffeine. However, the researchers state that they do not fully understand the exact relationship between dietary caffeine from coffee, tea, or other sources.

However, some people may find reducing or eliminating caffeine helpful.

Learn more about caffeine here.

Nightshades include the following vegetables:

One study indicated that people living with psoriasis often avoid nightshades because they believe it helps with their psoriasis symptoms.

However, the Global Healthy Living Foundation states that the number of nightshades a person typically eats would not be enough to trigger an inflammatory response. Though they focused primarily on arthritis, researchers believe the same chemicals trigger psoriasis responses.

Still, some people may find that reducing their consumption of nightshades may help reduce their psoriasis symptoms.

Learn whether nightshades worsen inflammation here.

During a 2017 study on the effects of certain foods on psoriasis flares, researchers found the following foods had a positive result on the skin symptoms of participants:

The National Psoriasis Foundation notes that no specific diet will cure psoriasis but may reduce the severity of the symptoms. They also note that eating healthier foods may help a person avoid other conditions, such as obesity and type 2 diabetes. They recommend eating:

Some people may find keeping a food journal helpful.

A food journal can help people look for patterns in what they eat and improve their psoriasis symptoms.

Learn more about how diet can affect psoriasis here.

Several environmental factors, or triggers, can cause psoriasis symptoms to flare.

Some potential psoriasis triggers include:

Some people may find they have other triggers. Others may be unable to identify their triggers.

A person should talk with their doctor about what may trigger their psoriasis flares if they have any questions.

Learn more about psoriasis triggers and how to avoid them here.

Certain foods may trigger psoriasis flares in some people.

A person can take steps, such as keeping a food journal, to help determine what foods may help and which may cause triggers.

Generally, the most helpful diets for psoriasis include fresh fruits, vegetables, lean proteins, low fat dairy, whole grains, and plant-based fats.

These diets may not help prevent a flare, but they may reduce symptom severity and help prevent other conditions, such as diabetes, obesity, or heart disease, from developing.

Go here to read the rest:
Foods to avoid with psoriasis: Types, diets, and more - Medical News Today

Several research articles have shown a positive association between psoriasis and thyroid diseases, including Hashimotos thyroiditis (hypothyroidism) and Graves disease (hyperthyroidism), but the limited number of studies do not provide a complete explanation to prove this association, according to a review study published in Cureus.

This review study included 45 articles that featured psoriasis, hypothyroidism, thyroid function tests, propylthiouracil, and psoriatic arthritis as inclusion keywords. Medical Subject Headings keywords psoriasis, hypothyroidism, and autoimmunity were also imputed into PubMed to identify the relevant articles for review.

A total of 39 of the 45 articles included in this review study demonstrated a positive association between psoriasis and thyroid diseases, although 6 articles found no association.

Continue Reading

In 5 articles, researchers showed that thyroid hormones had an effect on the development of psoriasis. Other articles demonstrated that genetic, immunological, and inflammation were involved in the associations. Reactive oxygen species-related pathogenesis was also reported in 2 articles. In 5 articles, there were reports of positive thyroid peroxidase antibodies, thyroglobulin antibodies, and Hashimotos thyroiditis ultrasound features in patients with psoriasis.

Marked improvement was observed in psoriatic skin lesions following thyroidectomy in 2 articles. In addition, the investigators of this review found that first-line propylthiouracil for hyperthyroidism reportedly clears psoriatic lesions, according to findings in 6 articles. Propylthiouracil did not appear to induce clinical hypothyroidism or lead to any serious adverse effects. The researchers of this review study suggest propylthiouracil could be prescribed as an alternative therapy for patients with psoriasis due to its side effects compared with existing psoriasis treatments that are typically toxic and expensive.

The investigators also noted that a higher prevalence of the association between psoriasis and thyroid diseases in women was reported in some of the articles. However, some articles found no sex preference involved in the prevalence of the association.

Limitations of this study included the small number of articles available for review as well as the lack of a pooled meta-analysis of the data.

The investigators concluded that additional studies are required to establish a connection between these diseases because these findings have a significant impact on both the clinical and research sides.

Eapi S, Chowdhury R, Lawal OS, Mathur N, Malik BH. Etiological association between psoriasis and thyroid diseases. Cureus. 2021;13(1):e12653. Published 2021 Jan 12. doi:10.7759/cureus.12653

This article originally appeared on Dermatology Advisor

Read the original post:
Is There an Association Between Psoriasis/PsA and Thyroid Disease? - Rheumatology Advisor

PRINCETON, N.J., April 22, 2021 /PRNewswire/ --Sun Pharmaceutical Industries Inc., USA (Sun Pharma) today announced that 12 data abstracts for ILUMYA (tildrakizumab-asmn) in patients with moderate-to-severe plaque psoriasis will be presented at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX) 2021, taking place April 23-25. The data to be highlighted at this year's meeting reinforce Sun Pharma's commitment to continuing to research the long-term efficacy and safety of ILUMYA, one of the most studied IL-23 inhibitors in market.

Click to TweetNEWS: @SunPharma_Live announces 12 data abstracts revealing long-term sustained efficacy and safety results for its treatment in moderate-to-severe plaque psoriasis at #AADVMX2021. Read more: bit.ly/3tu3UmR

"We are proud to be presenting data abstracts on ILUMYA for patients with moderate-to-severe plaque psoriasis at this year's AAD VMX," said Abhay Gandhi, CEO, Sun Pharma, North America. "The data being presented underscore our dedication to providing ongoing clinical insights into the long-term efficacy and safety of ILUMYA, an IL-23 inhibitor that helps balance the immune system from the inside out to help patients keep their moderate-to-severe plaque psoriasis under control."

ILUMYA abstracts to be presented at AAD VMX 2021

*Abstract sponsored byAlmirallwho marketstildrakizumab-asmnin the EU.

The AAD Virtual Meeting Experience 2021 is accessible via registration here.

About thereSURFACEExtensionStudies

The Phase-3 studies (reSURFACE 1 and reSURFACE 2) were randomized, placebo-controlled, multicenter, three-part studies designed toevaluateefficacyand safetyof ILUMYA100 mg and 200 mgin moderate-to-severe plaque psoriasis compared to placebo and comparative drugand to assess safety and tolerability.Participants with at least a PASI 50 response at base study completion who received ILUMYA within 12 weeks of base study end (week52 or64) were eligible to enroll in the extension study andcontinuedonthe same ILUMYA dose once every 12 weeks.Researchers evaluated PASI responses and PGA score of 0 or 1 with 2 grade reduction from baseline, and incidence rates for adverse events, including severe infections, cardiovascular events, and drug-related hypersensitivities.

About ILUMYA(tildrakizumab-asmn)

ILUMYA (tildrakizumab-asmn) is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23 (IL-23) and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMYA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, in the United States. ILUMYAhas also been approved for moderate-to-severe plaque psoriasis in Australia and Japan, and under the brand name ILUMETRI in Europe.

IMPORTANT SAFETY INFORMATION

ILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any other excipients.

Cases of angioedema and urticaria occurred in ILUMYA-treated subjects in clinical trial. If a serious hypersensitivity reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy.

ILUMYA may increase the risk of infection. Treatment with ILUMYA should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated. Consider the risks and benefits of treatment prior to prescribing ILUMYA in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue ILUMYA until the infection resolves.

Evaluate patients for TB infection prior to initiating treatment with ILUMYA. Do not administer ILUMYA to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA. Consider antiTB therapy prior to initiation of ILUMYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA should be monitored closely for signs and symptoms of active TB during and after ILUMYA treatment.

Prior to initiating therapy with ILUMYA, consider completion of all age-appropriate immunizations according to current immunization guidelines. Patients treated with ILUMYA should not receive live vaccines.

Most common (1%) adverse reactions associated with ILUMYA include upper respiratory infections, injection site reactions, and diarrhea. Adverse reactions that occurred at rates less than 1% but greater than 0.1% in the ILUMYA group and at a higher rate than in the placebo group included dizziness and pain in extremity.

About Sun Dermatology

Sun Dermatology (the branded dermatology division of Sun Pharmaceutical Industries Inc. in the United States) is committed to expanding its dermatology portfolio to bring more treatment options and ongoing support for healthcare providers and patients around the world. For more than 30 years, it has been dedicated to advancing the science of dermatology for a variety of conditions like plaque psoriasis, severe nodular acne, minimally to moderately thick actinic keratoses of the face, scalp or upper extremities, and locally advanced basal cell carcinoma. Sun Pharmaceutical Industries Ltd., along with its subsidiaries, is ranked second in dermatology prescription volume within the U.S. per IQVIA and is the fourth largest specialty generic pharmaceutical company globally.

About Sun Pharmaceutical Industries Inc., USA

Sun Pharma is a wholly owned subsidiary of Sun Pharmaceutical Industries Limited (SPIL). SPIL is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. SPIL fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6% of annual revenues in R&D. For further information, please visit http://www.sunpharma.com & follow us on Twitter @SunPharma_Live.

DisclaimerStatements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

Contact:

Media:

Gaurav Chugh

Tel

+91 22 4324 4324, Xtn 5373

Tel Direct

+91 22 4324 5373

Mobile

+91 98104 71414

Email

[emailprotected]

SOURCE Sun Pharma

Originally posted here:
Sun Pharma to Present Clinical Data Abstracts for ILUMYA (tildrakizumab-asmn) in Patients with Moderate-to-Severe Plaque Psoriasis at the AAD Virtual...

WESTLAKE VILLAGE, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.(Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology,will present new data from three studies evaluating the safety, efficacy, and tolerability of its once-daily, topical roflumilast cream and foam at the American Academy of Dermatology Virtual Meeting Experience (VMX) April 23 - 25,2021.

Patients suffering from plaque psoriasis, scalp psoriasis, and seborrheic dermatitis have significant unmet needs given the lack of efficacious, safe, tolerable topical options for long-term use, said Patrick Burnett, M.D., Ph.D., FAAD, Chief Medical Officer, Arcutis. We are pleased to share these new data that further reinforce the potential of roflumilast cream and foam in various inflammatory skin diseases. If approved by the FDA, our therapies could change the treatment paradigm for patients and their providers in addressing challenging inflammatory dermatological conditions that can significantly impact quality of life.

The data include positive results from a Phase 2b study of roflumilast foam for the treatment of scalp and body psoriasis, as well as a Phase 2 study of roflumilast foam in patients with seborrheic dermatitis.

Two additional poster slide presentations will feature sub-analyses from the previously published Phase 2b study of roflumilast cream in the treatment of chronic, mild-to-severe plaque psoriasis: 1) the correlation of itch response toroflumilast creamwithdisease severity andpatient-reported outcomes, and 2) the treatment of steroid-sensitive areas of the body including the face, neck, and intertriginous areas.

Finally, Dr. Kim Papp will present results from a new measurement, PASI-HD, which he developed in conjunction with the Arcutis medical team and which was used in the Phase 2b study of roflumilast cream in plaque psoriasis. In areas where the affected body surface area is low (<10%), PASI-HD better distinguishes disease severity than the traditional Psoriasis Area and Severity Index (PASI), which is a gold standard measure in psoriasis clinical trials.

Details of Arcutis AAD Virtual Congress presentations include:

Roflumilast is a highly potent phosphodiesterase-4 (PDE4) inhibitor in development for plaque psoriasis (PsO). Arcutis is investigating roflumilast as a once-daily, nonsteroidal, topical treatment for plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis.

For more information, visithttps://www.arcutis.comor follow the company onLinkedInandTwitter. Join the conversation with the hashtag #AADVMX2021.

About PsoriasisPsoriasis is a common, non-contagious, immune-mediated skin disease that affects approximately 8.6 million patients in the United States. About 90% of patients develop plaque psoriasis, which is characterized by raised, red areas of skin covered with a silver or white layer of scale. Psoriatic plaques can appear on any area of the body, but most often appear on the scalp, knees, elbows, trunk, and limbs, and are often itchy and sometimes painful.

Scalp psoriasis is a manifestation of plaque psoriasis characterized by plaques in the hair-bearing area of the scalp and sometimes extending to the forehead, back of the neck, or behind or inside the ears. Patients with scalp psoriasis commonly have plaques on other areas of the body as well. Scalp psoriasis is present in nearly half of Americans with psoriasis. As with psoriatic plaques on other parts of the body, scalp psoriasis is often itchy and sometimes painful. It can also be associated with hair loss.

About Seborrheic DermatitisSeborrheic dermatitis affects more than 10 million people in the United States, and is a common, chronic, or recurrent inflammatory skin disease that causes red patches covered with large, greasy, flaking yellow-gray scales, and persistent itch. Seborrheic dermatitis occurs most often on the scalp, face (especially on the nose, eyebrows, ears, and eyelids), upper chest, and back.

About Topical Roflumilast Cream and FoamRoflumilast Cream and Foam are once-daily, topical formulations of a highly potent and selective PDE4 inhibitor (roflumilast). The foam formulation was developed to treat inflammatory dermatoses in hair-bearing areas of the body, such as the scalp, although it is usable in all areas of the body. Roflumilast has been approved by the U.S. Food and Drug Administration (FDA) for oral treatment to reduce the risk of exacerbations of chronic obstructive pulmonary disease (COPD) since 2011. Roflumilast has shown greater potency (25- to 300-fold) than the two other FDA-approved PDE4 inhibitors for dermatology. PDE4 is an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases production of anti-inflammatory mediators and has been implicated in a wide range of inflammatory diseases including psoriasis, atopic dermatitis, and COPD. PDE4 is an established target in dermatology, and other PDE4 inhibitors have been approved by the FDA for the topical treatment of atopic dermatitis and the systemic treatment of plaque psoriasis.

About ArcutisArcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis robustpipelineincludes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The companys lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visithttps://www.arcutis.comor follow the company onLinkedIn andTwitter.

Forward Looking StatementsThis press release contains "forward-looking" statements, including, among others, statements regarding the potential for roflumilast to revolutionize the standard of care in plaque psoriasis and other inflammatory dermatological conditions. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the "Risk Factors" section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 16, 2021, as well as any subsequent filings with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Investor and Media Contact:Heather Rowe Armstrongharmstrong@arcutis.com805-418-5006 ext. 740

See the rest here:
Arcutis Biotherapeutics to Present New Roflumilast Data at The American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) - GlobeNewswire

Inflammatory skin conditions may be associated with higher risk for COVID-19, study data published in the Journal of Allergy and Clinical Immunology suggests. In a subsequent gene expression analyses, shared genetic components were also identified in certain skin conditions and the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Investigators conducted an epidemiological study of patients with COVID-19 followed by an analysis of bronchial epithelial cells infected with SARS-CoV-2. Medical records data were extracted from a health system in Michigan. COVID-19 and inflammatory skin conditions were identified using the appropriate diagnostic codes. Multiple logistic regression was used to identify the medical comorbidities were associated with COVID-19 and with severe disease outcomes. Models were adjusted for age, sex, race/ethnicity, obesity, and socioeconomic status. For the transcriptome analysis, investigators compared gene expression across 9 inflammatory skin conditions and bronchial epithelial cells infected with SARS-CoV-2. Data were also abstracted from a prior genetic meta-analysis of COVID-19 susceptibility to identify potential shared loci between COVID-19 and inflammatory skin conditions.

Medical data were available for 1115 patients with COVID-19, of whom 105 (9.4%) had acne, 38 (3.4%) had atopic dermatitis, 36 (3.2%) had psoriasis, and 35 (3.1%) had rosacea. In logistic regression models, atopic dermatitis (odds ratio [OR], 1.48; 95% confidence interval [CI], 1.06-2.06; P =.020) and psoriasis (OR, 1.48; 95% CI, 1.06-2.07; P =.0.22) were associated with increased odds of COVID-19. However, inflammatory skin conditions appeared to be associated with lower risk for severe COVID-19 outcomes. Specifically, having any skin condition appeared to substantially decrease the odds for ventilation (OR, 0.22; 95% CI, 0.11-0.47; P = 8.5 10-5).

Continue Reading

In the transcriptome portion of the study, substantial overlap was observed in gene expression between bronchial epithelial cells infected with SARS-CoV-2 and lesion cells with inflammatory skin disease. In addition, epidermal differentiation complex (EDC) genes were found to be upregulated in both SARS-CoV-2 infection and in inflammatory skin conditions. A shared locus in the EDC was also detected between psoriasis and COVID-19 infection (P = 3.3 10-7).

Findings from this multi-omics study underscore a potential association between inflammatory skin conditions and COVID-19. Interestingly, diagnosis with psoriasis or atopic dermatitis appeared to decrease the risk for ventilation with COVID-19. Preliminary genetic data also highlight a potential shared genomic component. [Although] the epidemiological and genetic findings require additional validation and replicationthis work will serve as an important study to reveal individuals that are more susceptible to infection of SARS-CoV-2, and how their pre-existing conditions may affect the course of the disease, investigators wrote.

Disclosure: Two study authors declared affiliations with the pharmaceutical industry

Please see the original reference for a full list of authors disclosures.

Patrick MT, Zhang H, Wasikowski R, et al. Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies Published online January 21, 2021. J Allergy Clin Immunol. doi: 10.1016/j.jaci.2021.01.006

This article originally appeared on Dermatology Advisor

Go here to read the rest:
Investigating the Relationship Between Inflammatory Skin Diseases and COVID-19 - Rheumatology Advisor

Rich Insights into Plaque Psoriasis Market, Patient Pool, Pipeline Therapies, Key Companies working in the Space and Emerging Trends

DelveInsights Plaque Psoriasis Market Insights Report offers a detailed analysis of disease, its causes, symptoms, diagnostics modalities and treatment options.

The report also offers comprehensive insights into Plaque Psoriasis market size, epidemiology, emerging therapies, market drivers, market barriers, ongoing clinical trials, key collaboration in the space, and key pharmaceutical companies actively pushing the growth of market size forward.

Some of the key highlights from the Plaque Psoriasis Market Insights:

Learn more by requesting for sample @ Plaque Psoriasis Market Landscape

Plaque Psoriasis: Overview

Psoriasis is a common skin condition that speeds up the life cycle of skin cells. It causes cells tobuild up rapidly on the surface of the skin. The extra skin cells form scales and red patches that are itchy and sometimes painful.

The characteristic signs and symptoms of psoriasis are small scaly, red bumps. These bumps generally join together into elevated plaques of skin and most often are visible on the elbows, knees, and scalp, although any area of skin can be involved. Frequently, these plaques are quite itchy. Rarely, most of the patients skin surface is affected.

For more insights into Disease, causes and treatment, reach out @ Plaque Psoriasis Treatment Landscape

Plaque Psoriasis Epidemiology Segmentation

The Plaque Psoriasis Market report proffers epidemiological analysis for the study period 2017-30 in the 7MM segmented into:

Visit for more @ Plaque Psoriasis Epidemiological Insights

Plaque Psoriasis Market

Plaque Psoriasis Market size is expected to expand owing to the launch of several emerging therapies, key companies working in the space, rising prevalence, increment in R&D in the field, medical advancements happening in the Plaque Psoriasis market domain.

Plaque Psoriasis Pipeline Therapies and Key Companies

For more information, visit Plaque Psoriasis Market Analysis, Patient Pool and Emerging Therapies

Plaque Psoriasis Market Drivers

Scope of the Report

Key Questions Answered in the Report

Get in touch with our Business executive @ Plaque Psoriasis Market Landscape Analysis

Table of Contents

Learn more about the report offerings @ Plaque Psoriasis Market Outlook

Related Reports

Glioblastoma Multiforme Market

DelveInsights Glioblastoma Multiforme (GBM) Market Insights, Epidemiology and Market Forecast 2030 report.

Glioma Market

DelveInsights Glioma Market Insights, Epidemiology, and Market Forecast-2030 report.

Gliosarcoma Market

DelveInsights Gliosarcoma Market Insights, Epidemiology, and Market Forecast-2030 report.

High-Grade Glioma Market

DelveInsights High-grade Glioma (HGG) Market Insights, Epidemiology and Market Forecast 2030 report.

Malignant Glioma Market

DelveInsights Malignant Glioma Market Insights, Epidemiology, and Market Forecast-2030 report.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences providing end-to-end comprehensive solutions to improve their performance.

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Tags: PsoriasisEpidemiology, PlaquePsoriasisMarket, PlaquePsoriasis, Psoriasispipeline, Psoriasismarket, Plaque, Psoriasis

Read the original:
Rich Insights into Plaque Psoriasis Market, Patient Pool, Pipeline Therapies, Key Companies working in the Space and Emerging Trends Wall Street Call...

Psoriasis Drugs Market

Global Psoriasis Drugs Market Insights, Forecast To 2027 provides a specific tool for evaluating the global market, specifying the growth potentials, and supporting tactical and strategic decision-making. This report identifies that in this quickly developing and competitive world, the latest marketing information is essential, in order to monitor performance and make strategic decisions for development and profitability. This report provides information on the overall market trends and development patterns, as well as focuses on the markets and materials, capacities and technologies, and on the dynamic nature of the Psoriasis Drugs market.

UCB, Amgen, Novartis, AbbVie, Johnson & Johnson, Cytech Industries, Merck

The Psoriasis Drugs Market is separated according to Types and End Users.

On the basis of the Types, the market is classified as:Interleukin Inhibitors, Tumor Necrosis Factor Inhibitor, Others,

On the basis of the application, the market is classified as:Topicals,Systemic,Biologics,

For market chain analysis, the report focuses on the upstream raw materials, downstream demand analysis, distribution/marketing channels, market trends, governing factors, development patterns, and proposals, which particularly include relevant data on the Psoriasis Drugs key applications and consumption, major geographies, consumption and production rate, supply chain relationship analysis, major global distributors, major raw material suppliers and manufacturing equipment suppliers, key consumers, as well as the contact information of all the major suppliers and distributors.

2015

2020

2027

Share (%)

This report assesses the growth rate and the market value on the basis of the key Psoriasis Drugs market dynamics, as well as the growth inducing factors. The complete study is based on the up-do-date industry news, growth potentials, and market trends. It also contains an in-depth analysis of the market and competitive scenario, together with the SWOT analysis of the leading competitors.

This research Psoriasis Drugs study consists of the historical data from 2015 to 2020 and forecasts until 2027, which makes it a valuable source of information for all the individuals looking for relevant market information in readily accessible documents with clearly presented graphs and statistics, including but not limited to the industry executives, analysts, consultants, and marketing, sales, and product managers.

Mention your questions here to receive a call from our industry experts@sales@regalintelligence.com

About Us:We, Regal Intelligence, aim to change the dynamics of market research backed by quality data. Our analysts validate data with exclusive qualitative and analytics driven intelligence. We meticulously plan our research process and execute in order to explore the potential market for getting insightful details. Our prime focus is to provide reliable data based on public surveys using data analytics techniques. If you have come here, you might be interested in highly reliable data driven market insights for your product/service, reach us here 24/7.

Contact Us:Regal Intelligence: http://www.regalintelligence.comPh no: +1 231 930 2779 (U.S.) | +44 141 628 8787 (UK)

Continued here:
Key Vendors of Psoriasis Drugs Market: UCB, Amgen, Novartis, AbbVie, Johnson & Johnson, and others The Courier - The Courier